Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin i - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Stati Uniti - Ingliż - NLM (National Library of Medicine)

physicians total care, inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - instructions for insulin vial use never share needles and syringes. correct syringe type doses of insulin are measured in units . u–100 insulin contains 100 units/ml (1 ml=1 cc). with humulin n, it is important to use a syringe that is marked for u–100 insulin preparations. failure to use the proper syringe can lead to a mistake in dosage, causing serious problems for you, such as a blood glucose level that is too low or too high. syringe use to help avoid contamination and possible infection, follow these instructions exactly. disposable syringes and needles should be used only once and then discarded by placing the used needle in a puncture-resistant disposable container. properly dispose of the puncture-resistant container as directed by your health care professional. preparing the dose - wash your hands. wash your hands. - carefully shake or rotate the bottle of insulin several times to completely mix the insulin. carefully shake or rotate the bottle of insulin several times to completely mi

Stati Uniti - Ingliż - NLM (National Library of Medicine)

physicians total care, inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - instructions for insulin vial use never share needles and syringes correct syringe type doses of insulin are measured in units . u–100 insulin contains 100 units/ml (1 ml=1 cc). with humulin 70/30, it is important to use a syringe that is marked for u–100 insulin preparations. failure to use the proper syringe can lead to a mistake in dosage, causing serious problems for you, such as a blood glucose level that is too low or too high. syringe use to help avoid contamination and possible infection, follow these instructions exactly. disposable syringes and needles should be used only once and then discarded by placing the used needle in a puncture-resistant disposable container. properly dispose of the puncture-resistant container as directed by your health care professional. preparing the dose - wash your hands. wash your hands. - carefully shake or rotate the bottle of insulin several times to completely mix the insulin. carefully shake or rotate the bottle of insulin several times to completely

Stati Uniti - Ingliż - NLM (National Library of Medicine)

tya pharmaceuticals - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - important: do not change the type of insulin you use unless told to do so by your healthcare provider. the amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin. know your insulin. make sure that you know the type and strength of insulin that is prescribed for you. read the patient information leaflet that comes with novolin 70/30 before you start taking it and each time you get a refill. there may be new information. this leaflet does not take the place of talking with your healthcare provider about your diabetes or your treatment. make sure you know how to manage your diabetes. ask your healthcare provider if you have any questions about managing your diabetes. ® what is novolin 70/30? ® novolin 70/30 is a man-made insulin (recombinant dna origin) which is a mixture of 70% nph, human insulin isophane suspension and 30% regular, human in

Stati Uniti - Ingliż - NLM (National Library of Medicine)

novo nordisk - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - novolin 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. limitations of use: in novolin 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. novolin 70/30 is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general

Stati Uniti - Ingliż - NLM (National Library of Medicine)

physicians total care, inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - important: know your insulin. do not change the type of insulin you use unless told to do so by your healthcare provider. the amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin. make sure that you know the type and strength of insulin that is prescribed for you. read the patient information leaflet that comes with novolin 70/30 before you start taking it and each time you get a refill. there may be new information. this leaflet does not take the place of talking with your healthcare provider about your diabetes or your treatment. make sure you know how to manage your diabetes. ask your healthcare provider if you have any questions about managing your diabetes. what is novolin 70/30? novolin 70/30 is a man-made insulin (recombinant dna origin) which is a mixture of 70% nph, human insulin isophane suspension and 30% regular, human insulin injection that is structurally identical to the insulin produced by the human pancrea

Stati Uniti - Ingliż - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin n is an intermediate-acting recombinant human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. humulin n is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] , and - in patients who have had hypersensitivity reactions to humulin n or any of its excipients [see warnings and precautions (5.4)] . pregnancy category b risk summary all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline a

Stati Uniti - Ingliż - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin 70/30 is a fixed ratio premix recombinant human insulin formulation indicated to improve glycemic control in adult patients with diabetes mellitus. humulin 70/30 is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)], and - in patients who have had hypersensitivity reactions to humulin 70/30 or any of its excipients [see warnings and precautions (5.4)] . pregnancy category b risk summary all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly de

Filippini - Ingliż - FDA (Food And Drug Administration)

zuellig pharma corp.; distributor: zuellig pharma corp. - isophane insulin human (recombinant dna) 70% isophane insulin , 30% soluble insulin - suspension for injection (s.c.) - 100 units/ml

Filippini - Ingliż - FDA (Food And Drug Administration)

ambica international corporation; distributor: gx international, inc. - isophane insulin human, recombinant dna - suspension for injection (sc) - 100 i.u./ml